Laura Zorzino

Dr. Laura Zorzino

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 April 2014 in Breast Cancer Research
Verified
Journal Article
Open access
PDF file
MIMichail Ignatiadis
Michail Ignatiadis
SRSabine Riethdorf
Sabine Riethdorf
FBFrancois-Clement Bidard
Francois-Clement Bidard
IVIsabelle Vaucher
Isabelle Vaucher
MKMustapha Khazour
Mustapha Khazour
KPKlaus Pantel
Klaus Pantel
Introduction: Circulating tumor cells (CTCs) have been studied in breast cancer with the CellSearch® system. Given the low CTC counts in non-metastatic breast cancer, it is important to evaluate the inter-reader agreement. Methods: CellSearch® images (N = 272) of either CTCs or white blood cells or artifacts from 109 non-metastatic (M0) and 22 metastatic (M1) breast cancer patients from reported studies were sent to 22 readers from 15 academic laboratories and 8 readers from two Veridex laboratories. Each image was scored as No CTC vs CTC HER2- vs CTC HER2+. The 8 Veridex readers were summarized to a Veridex Consensus (VC) to compare each academic reader using % agreement and kappa (κ) statistics. Agreement was compared according to disease stage and CTC counts using the Wilcoxon signed rank test. Results: For CTC definition (No CTC vs CTC), the median agreement between academic readers and VC was 92% (range 69 to 97%) with a median κ of 0.83 (range 0.37 to 0.93). Lower agreement was observed in images from M0 (median 91%, range 70 to 96%) compared to M1 (median 98%, range 64 to 100%) patients (P < 0.001) and from M0 and <3CTCs (median 87%, range 66 to 95%) compared to M0 and ≥3CTCs samples (median 95%, range 77 to 99%), (P < 0.001). For CTC HER2 expression (HER2- vs HER2+), the median agreement was 87% (range 51 to 95%) with a median κ of 0.74 (range 0.25 to 0.90). Conclusions: The inter-reader agreement for CTC definition was high. Reduced agreement was observed in M0 patients with low CTC counts. Continuous training and independent image review are required.

15 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
CCChiara Alessandra Cella
Chiara Alessandra Cella
FSFrancesca Spada
Francesca Spada
ABAlfredo Berruti
Alfredo Berruti
Francesco BertoliniFrancesco Bertolini
Francesco Bertolini
PMPATRIZIA MANCUSO
PATRIZIA MANCUSO
NFNicola Fazio
Nicola Fazio
Background: The success of targeted therapies in the treatment of pancreatic neuroendocrine tumors has emphasized the strategy of targeting angiogenesis and the PI3K/AKT/mTOR pathway. However, the major challenge in the targeted era remains the early identification of resistant tumors especially when the efficacy is rarely associated to a clear tumor shrinkage at by imaging assessment. Methods: In this prospective study (NCT02305810) we investigated the predictive and prognostic role of soluble biomarkers of angiogenesis turnover (VEGF, bFGF, VEGFR2, TSP-1) circulating endothelial cells and progenitors, in 43 patients with metastatic panNET receiving everolimus. Results: Among all tested biomarkers, we found a specific subpopulation of circulating cells, CD31+CD140b-, with a significantly increased tumor progression hazard for values less or equal to the first quartile. Conclusion: Our study suggested the evidence that circulating cells might be surrogate biomarkers of angiogenesis activity in patients treated with everolimus and their baseline levels can be correlated with survival. However, further studies are now needed to validate the role of these cells as surrogate markers for the selection of patients to be candidates for antiangiogenic treatments.

Verified
Journal Article
Open access
PDF file
JGJuliana Guarize
Juliana Guarize
CDCristina Diotti
Cristina Diotti
MCMonica Casiraghi
Monica Casiraghi
SDStefano Donghi
Stefano Donghi
CTClementina Di Tonno
Clementina Di Tonno
LSLorenzo Spaggiari
Lorenzo Spaggiari
Background. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) is a well-established diagnostic procedure for evaluating hilar and mediastinal lymphadenopathies and is the gold standard for lung cancer diagnosis and staging. Recent studies assessed the effectiveness of the 19-G flex needle in obtaining larger EBUS-TBNA samples, and prospective small series gave similar results in terms of diagnostic yield when testing different gauge needles. The lack of homogeneity between series and the small sample size of some prospective cohorts poses a limit to the validity of those results. This prospective controlled study compared the 19-G flex and 22-G needles in terms of diagnostic yield. An objective laboratory method was used to count cells and compare the two needles’ cytologic yields. Material. A prospective controlled study was conducted on 90 patients undergoing EBUS-TBNA for the diagnosis of hilar and mediastinal lymphadenopathies. The institutional ethic committee (IEO573) approved the study, and informed consent was obtained from all patients. Results. A total of 90 patients were enrolled in this study, 84.4% of whom were diagnosed with malignancy and 15.6% with non-neoplastic disease. Sensitivity for malignancy was 93.4% (CI: 87.4–97.1%) for the 19-G needle and 92.6% (CI: 86.3–96.5%) for the 22-G needle (p = 0.80). The percentage of malignant cells in the cell block was 63.9% and 61.5% for the 22-G and 19-G needles, respectively. The cell count assessed by flow cytometry was 2071 cells/µL (IQR: 600,2265) with the 22-G needle and 2761 cells/µL (IQR: 505,3250) with the 19-G needle (p = 0.79). The malignant cell count was 0.05 × 103 cells/µL with the 22-G and 0.08 × 103 cells/µL with the 19-G needle (p = 0.70). There was no difference in the presence of tissue cores in the samples, and rapid on-site evaluation (ROSE) cellularity was comparable between the two needles. Conclusions. The 19-G flex EBUS-TBNA needle is comparable to the 22-G needle in terms of diagnostic yield for cyto-histological evaluation of hilar and mediastinal lymphadenopathies. There is no difference between the 19-G and 22-G needle cell counts evaluated by flow cytometry.

13 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Francesco PetrellaFrancesco Petrella
Francesco Petrella
LZLaura Zorzino
Laura Zorzino
SFSamuele Frassoni
Samuele Frassoni
VBVincenzo Bagnardi
Vincenzo Bagnardi
MCMonica Casiraghi
Monica Casiraghi
LSLorenzo Spaggiari
Lorenzo Spaggiari
Background: The diagnosis of active neoplastic disease was traditionally judged an absolute contraindication for extracorporeal membrane oxygenator (ECMO) because of the fear of tumor cells being scattered or seeded. The aim of this study is to compare the number of circulating tumor cells (CTCs) before and after surgery in patients receiving lung cancer resection with and without intraoperative ECMO support. Methods: This is a prospective, non-randomized, two-arms observational study comparing the number of CTCs before and after surgery in patients receiving lung cancer resection with and without intraoperative ECMO support. The ECMO arm includes patients suffering from lung cancer undergoing pulmonary resection with planned intraoperative ECMO support. The non-ECMO arm includes patients suffering from non-early-stage lung cancer undergoing pulmonary resection without planned intraoperative ECMO support. Results: Twenty patients entered the study, eight in the ECMO arm and twelve in the non-ECMO arm. We did not observe any significant difference between the ECMO and non-ECMO groups in terms of postoperative complications (p = 1.00), ICU stay (p = 0.30), hospital stay (p = 0.23), circulating tumor cells’ increase or decrease after surgery (p = 0.24), and postoperative C-reactive protein and C-reactive protein increase (p = 0.80). The procedures in the non-ECMO arm were significantly longer than those in the ECMO arm (p = 0.043). Conclusions: Intraoperative ECMO for lung cancer resections did not impact CTC increase or decrease after the procedure.

15 December 2010
Verified
Conference Paper
Closed access
EMelisabetta munzone
elisabetta munzone
EBEdoardo Botteri
Edoardo Botteri
FNF Nolè
F Nolè
Anna EspositoAnna Esposito
Anna Esposito
LAL Adamoli
L Adamoli
MSMt. Sandri
Mt. Sandri
Background: Breast cancer (BC) is not a single disease with variable morphologic features and biomarkers but, rather, a group of molecularly distinct neoplastic disorders. Four main molecular classes of BC have been distinguished by gene expression profiling, called luminal-A, luminal-B, HER2-positive and triple-negative (TN) cancers. These subgroups correspond reasonably well to clinical characterization on the basis of estrogen receptor (ER) and HER2 status, as well as proliferation markers or histologic grade. Correlating circulating tumor cells (CTCs) with molecular subtypes might identify subgroup of patients (pts) at different risks and groups that might benefit more from prognostic evaluation by CTCs. Patients and methods: We retrospectively analyzed 187 consecutive metastatic BC pts who had baseline CTCs enumeration performed between March 2005 and December 2009 by CellSearch. Pts were categorized in 3 prognostic groups in accordance to the number of CTCs, 0 CTC, 1%, any progesterone receptor (PgR), G1/G2, Ki671%, any PgR, G3, Ki67>30%; HER-2 positive with HER-2 overexpressed or FISH amplified; TN with both ER and PgR 0% and HER-2 not overexpressed/FISH not amplified. Kaplan-Meier method for survival analysis was used. Results: Median age at baseline was 56 years (range 31-78). CTCs were a strong predictive factor for overall survival (OS) in all pts (Log-Rank P<0.001), in pts with bone metastases (MTS) only (n=43; p=0.045), visceral MTS only (n=42; borderline significant p=0.08) and both bone and visceral MTS (n=74; P<0.001). The same figure was not observed in the few pts with only soft tissue MTS (n=28; p=0.315). Sixty-one (33%) pts had Luminal-A tumour, 58 (31%) Luminal-B, 53 (28%) HER-2 positive and 15 (8%) TN. CTCs were a significant prognostic factor in all molecular subtypes as shown in Figure 1. Conclusion: This large series confirms CTCs as an important prognostic factor for metastatic BC in all different molecular subtypes, but pts with 0 CTCs at baseline and TN or luminal B tumors seem to perform better as compared to other categories. Furthermore, pts with metastatic disease including bone and/or visceral sites benefited most from CTCs prognostic evaluation. Further studies with larger series and longer follow-up time could help identify metastatic BC subgroups in which CTCs analysis would be particularly useful and should be recommended. Figure available in online version. Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr PD04-05.